These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36620892)

  • 41. A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial.
    Boinpally R; McNamee B; Yao L; Butler M; McGeeney D; Borbridge L; Periclou A
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1099-1107. PubMed ID: 33942560
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials.
    Tao X; Yan Z; Meng J; Wang W; Dai Q; Zhou Q; Wang Z; Wang Z
    J Headache Pain; 2022 Jan; 23(1):19. PubMed ID: 35093013
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.
    Dodick DW; Freitag F; Banks J; Saper J; Xiang J; Rupnow M; Biondi D; Greenberg SJ; Hulihan J;
    Clin Ther; 2009 Mar; 31(3):542-59. PubMed ID: 19393844
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.
    Skljarevski V; Oakes TM; Zhang Q; Ferguson MB; Martinez J; Camporeale A; Johnson KW; Shan Q; Carter J; Schacht A; Goadsby PJ; Dodick DW
    JAMA Neurol; 2018 Feb; 75(2):187-193. PubMed ID: 29255900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Sun H; Dodick DW; Silberstein S; Goadsby PJ; Reuter U; Ashina M; Saper J; Cady R; Chon Y; Dietrich J; Lenz R
    Lancet Neurol; 2016 Apr; 15(4):382-90. PubMed ID: 26879279
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Atogepant: First Approval.
    Deeks ED
    Drugs; 2022 Jan; 82(1):65-70. PubMed ID: 34813050
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
    Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
    Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a
    Lipton RB; Tepper SJ; Silberstein SD; Kudrow D; Ashina M; Reuter U; Dodick DW; Zhang F; Rippon GA; Cheng S; Mikol DD
    Cephalalgia; 2021 Jan; 41(1):6-16. PubMed ID: 33269951
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study.
    Silberstein S; Saper J; Berenson F; Somogyi M; McCague K; D'Souza J
    Neurology; 2008 Feb; 70(7):548-55. PubMed ID: 18268247
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies.
    Nahas SJ; Naegel S; Cohen JM; Ning X; Janka L; Campos VR; Krasenbaum LJ; Holle-Lee D; Kudrow D; Lampl C
    J Headache Pain; 2021 Nov; 22(1):141. PubMed ID: 34819017
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
    Ferrari MD; Diener HC; Ning X; Galic M; Cohen JM; Yang R; Mueller M; Ahn AH; Schwartz YC; Grozinski-Wolff M; Janka L; Ashina M
    Lancet; 2019 Sep; 394(10203):1030-1040. PubMed ID: 31427046
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Single-Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open-Label, Phase 1 Trial.
    Boinpally R; Jakate A; Butler M; Borbridge L; Periclou A
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):726-733. PubMed ID: 33501783
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
    Croop R; Goadsby PJ; Stock DA; Conway CM; Forshaw M; Stock EG; Coric V; Lipton RB
    Lancet; 2019 Aug; 394(10200):737-745. PubMed ID: 31311674
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.
    Dodick DW; Goadsby PJ; Spierings EL; Scherer JC; Sweeney SP; Grayzel DS
    Lancet Neurol; 2014 Sep; 13(9):885-92. PubMed ID: 25127173
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system.
    Smith TR; Goldstein J; Singer R; Pugach N; Silberstein S; Pierce MW
    Headache; 2012 Apr; 52(4):612-24. PubMed ID: 22352764
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study.
    Ferrari MD; Reuter U; Goadsby PJ; Paiva da Silva Lima G; Mondal S; Wen S; Tenenbaum N; Pandhi S; Lanteri-Minet M; Stites T
    J Neurol Neurosurg Psychiatry; 2022 Mar; 93(3):254-262. PubMed ID: 34845002
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review.
    Raffaelli B; De Icco R; Corrado M; Terhart M; Ailani J
    Cephalalgia; 2023 Feb; 43(2):3331024221137091. PubMed ID: 36718044
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
    Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
    Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
    Lipton RB; Dodick DW; Ailani J; Lu K; Finnegan M; Szegedi A; Trugman JM
    JAMA; 2019 Nov; 322(19):1887-1898. PubMed ID: 31742631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.